U.S. FDA·US·
FDA Approves New Engineered Viral Immunotherapy for Patients with Treatment-Resistant Advanced Melanoma
The U.S. Food and Drug Administration today granted accelerated approval to Tudriqev (vusolimogene oderparepvec-wtpg), a genetically modified oncolytic viral therapy for the treatment of advanced, refractory melanoma.
Read releases like this the second they cross the wire.
1,400+ feeds from 80+ newswires in one live cockpit — saved searches, instant alerts, AI summaries. 72-hour free trial, no card required.
Start the free trial →Your announcement next? Distribute your press release to the global wires with PPN Source — and track its pickup live on PPN World.
PPN Source →Shared via PPN World — real-time press release intelligence.